Online inquiry

IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9259MR)

This product GTTS-WQ9259MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CEACAM5 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001291484.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1048
UniProt ID P06731
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9259MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5151MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ14163MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ5306MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ2427MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ12884MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ10979MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ12065MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ10766MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW